I
ImmunoMolecular Therapeutics
Im therapeutics is working on a new platform for therapies that target the root cause of autoimmunity
About ImmunoMolecular Therapeutics
IM Therapeutics is a biotechnology company focused on developing personalized medicines for autoimmune diseases. The company operates in the healthcare and pharmaceutical markets, targeting conditions such as Type 1 Diabetes and Celiac Disease. Utilizing a unique approach, IM Therapeutics designs therapies that specifically block the action of HLA proteins, which are known to trigger autoimmune responses. The business model revolves around the research, development, and clinical trials of these novel therapies, with revenue generated through partnerships, grants, and eventual commercialization of successful treatments. The company serves patients suffering from autoimmune conditions, offering them innovative and targeted treatment options. IM Therapeutics is currently advancing its lead drug, IMT-002, through clinical trials and has shown promising safety data in early-phase studies.
Source: Dealroom company dataNews
Open roles
ImmunoMolecular Therapeutics in the Woburn ecosystem
The ImmunoMolecular Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Morningside Venture Partners
JDRF T1D Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ImmunoMolecular Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmunoMolecular Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
